Similar articles

• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD; ACT NOW Study. DeFronzo RA, et al. N Engl J Med. 2011 Mar 24;364(12):1104-15. doi: 10.1056/NEJMoa1010949. N Engl J Med. 2011. PMID: 21428766 Clinical Trial.
• Pioglitazone and bladder cancer: the pros and cons.

  Panikar V. Panikar V. J Assoc Physicians India. 2012 Jan;60:72-3. J Assoc Physicians India. 2012. PMID: 22715550 No abstract available.
• Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.

  Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, Koshiyama H. Fujimoto K, et al. Diabetes Res Clin Pract. 2013 Feb;99(2):e21-3. doi: 10.1016/j.diabres.2012.11.013. Epub 2012 Dec 7. Diabetes Res Clin Pract. 2013. PMID: 23228390
• The current role of thiazolidinediones in diabetes management.

  Rizos CV, Kei A, Elisaf MS. Rizos CV, et al. Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Arch Toxicol. 2016. PMID: 27165418 Review.
• Association between pioglitazone and urothelial bladder cancer.

  Barbalat Y, Dombrovskiy VY, Weiss RE. Barbalat Y, et al. Urology. 2012 Jul;80(1):1-4. doi: 10.1016/j.urology.2012.03.032. Epub 2012 May 23. Urology. 2012. PMID: 22626574 Review.